Abstract
Management of lupus nephritis (LN) has evolved considerably over the past years. Here we provide a comprehensive review of clinical trials that form the basis for the KDIGO and EULAR/ERA-EDTA updated guidelines and present-day trials that will change the landscape of LN therapy in years to come. Additionally, we highlight issues related to cost of therapy, resistant disease, and downstream adverse effects of specific therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
